{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:15:46Z","timestamp":1784632546658,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA37404"],"award-info":[{"award-number":["CA37404"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA35103"],"award-info":[{"award-number":["CA35103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA35431"],"award-info":[{"award-number":["CA35431"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA35269"],"award-info":[{"award-number":["CA35269"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA35415"],"award-info":[{"award-number":["CA35415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA63849"],"award-info":[{"award-number":["CA63849"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA25224"],"award-info":[{"award-number":["CA25224"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10549-020-05709-z","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T14:03:10Z","timestamp":1591365790000},"page":"613-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer"],"prefix":"10.1007","volume":"182","author":[{"given":"Roberto A.","family":"Leon-Ferre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celyne","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra T.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Northfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Carolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin T.","family":"Zon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-2580","authenticated-orcid":false,"given":"Alvaro","family":"Moreno-Aspitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"5709_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132\u20131139","journal-title":"Science"},{"key":"5709_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"5709_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/bjc.1992.22","volume":"65","author":"C Wright","year":"1992","unstructured":"Wright C, Nicholson S, Angus B et al (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118\u2013121","journal-title":"Br J Cancer"},{"key":"5709_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01961241","volume":"24","author":"CC Benz","year":"1992","unstructured":"Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res Treat 24:85\u201395","journal-title":"Breast Cancer Res Treat"},{"key":"5709_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/bjc.1991.103","volume":"63","author":"J Winstanley","year":"1991","unstructured":"Winstanley J, Cooke T, Murray GD et al (1991) The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447\u2013450","journal-title":"Br J Cancer"},{"key":"5709_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1634\/theoncologist.3-4-237","volume":"3","author":"JS Ross","year":"1998","unstructured":"Ross JS, Fletcher JA (1998) The HER-2\/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3:237\u2013252","journal-title":"Oncologist"},{"key":"5709_CR7","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366\u20133373","journal-title":"J Clin Oncol"},{"key":"5709_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"5709_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"5709_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"5709_CR11","doi-asserted-by":"crossref","unstructured":"Goldhirsch A, Piccart-Gebhart M, Procter M, et al (2012) HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 72:Abstract nr S5\u20132","DOI":"10.1158\/0008-5472.SABCS12-S5-2"},{"key":"5709_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","volume":"12","author":"L Gianni","year":"2011","unstructured":"Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236\u2013244","journal-title":"Lancet Oncol"},{"key":"5709_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617\u2013628","journal-title":"N Engl J Med"},{"key":"5709_CR14","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","volume":"21","author":"W Xia","year":"2002","unstructured":"Xia W, Mullin RJ, Keith BR et al (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways. Oncogene 21:6255\u20136263","journal-title":"Oncogene"},{"key":"5709_CR15","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"5709_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/biostatistics\/kxr054","volume":"13","author":"KD Hansen","year":"2012","unstructured":"Hansen KD, Irizarry RA, Wu Z (2012) Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13:204\u2013216","journal-title":"Biostatistics"},{"key":"5709_CR17","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1200\/JCO.2007.13.5202","volume":"26","author":"AM Storniolo","year":"2008","unstructured":"Storniolo AM, Pegram MD, Overmoyer B et al (2008) Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317\u20133323","journal-title":"J Clin Oncol"},{"key":"5709_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124\u20131130","journal-title":"J Clin Oncol"},{"key":"5709_CR19","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1200\/JCO.2009.26.5900","volume":"28","author":"C Dang","year":"2010","unstructured":"Dang C, Lin N, Moy B et al (2010) Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2\/neu-overexpressed\/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 28:2982\u20132988","journal-title":"J Clin Oncol"},{"key":"5709_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, Roth A, Goya R et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395\u2013399","journal-title":"Nature"},{"key":"5709_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J et al (2016) Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2\u2013positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol 34:1034","journal-title":"J Clin Oncol"},{"key":"5709_CR22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18\u201343","journal-title":"Arch Pathol Lab Med"},{"key":"5709_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10549-013-2469-2","volume":"138","author":"A Moreno-Aspitia","year":"2013","unstructured":"Moreno-Aspitia A, Dueck AC, Ghanem-Canete I et al (2013) RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat 138:427\u2013435","journal-title":"Breast Cancer Res Treat"},{"key":"5709_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, De Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122\u2013131","journal-title":"N Engl J Med"},{"key":"5709_CR25","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:1688\u20131700","journal-title":"Lancet Oncol"},{"key":"5709_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633\u2013640","journal-title":"Lancet"},{"key":"5709_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/jco.2013.31.15_suppl.500","volume":"31","author":"LA Carey","year":"2013","unstructured":"Carey LA, Berry DA, Ollila D et al (2013) Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 31:500","journal-title":"J Clin Oncol"},{"key":"5709_CR28","first-page":"S5","volume":"94","author":"D Slamon","year":"2005","unstructured":"Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC \u2192 T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC \u2192 TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05709-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:07:08Z","timestamp":1622851628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05709-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05709-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Leon Ferre reports travel support from Immunomedics, not relevant to the presented work. Dr. A. Perez reports institutional research support from Genentech, AstraZeneca, Immunomedics, Nektar and Macrogenics, not relevant to the presented work. Dr. Moreno-Aspitia reports institutional research funding from GlaxoSmithKline and Genentech, not relevant to the presented work. All remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}